We are a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well as drugs which may qualify to treat rare diseases. We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and will therefore be subject to reduced public company reporting requirements.
We are developing a peptide as a testosterone replacement therapy by stimulating the body's own production of testosterone rather than using synthetic steroid hormones. We believe that our peptide may be a safer alternative - to be proven after clinical studies - to currently available interventions for restoring testosterone levels in males. A second program of the company is a test for dementia which we believe will be the basis for developing an early stage blood or fluid test for Alzheimer's disease and other similar conditions. Based on the advice of our Scientific Advisory Board (SAB) and a meeting held on November 7, 2018, management has decided to focus the R&D efforts of the company on the peptide development whereas the dementia test remains an asset of the company which we will be seeking to out-license to a 3rd party for further development and commercialization.
A major part of our research and development activities was contracted out to the Research Institute of the McGill University Health Centre in Montreal Canada. The research team was led by Dr. Vassilios Papadopoulos, one of our founders and directors, who specializes in the biochemistry of steroids and their impact on human disease and use as biomarkers for detection of disease and who also serves as Chairman of our SAB. His research provides the foundation for our initial technologies and products. Dr Papadopoulos is currently the Dean of School of Pharmacy at USC.